Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
Kinga Malottki, Pelham Barton, Angelos Tsourapas, AO Uthman, Zulian Liu, Kristina Routh, Martin Connock, Paresh Jobanputra, David Moore, A Fry-Smith, Yen-Fu Chen
Research output: Contribution to journal › Article › peer-review
129Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation'. Together they form a unique fingerprint.